Connect with us

News

Advanced Micro Devices (AMD) Stock Price Soars 50% in 2019: What’s Next?

Joe Samuel

Published

on

AMD stock price

Over the course of the past few years, the Advanced Micro Devices, Inc. (AMD Stock Report) stock has been one of the more interesting stocks in the market and this year, it has made rapid moves. During the initial years after the IPO, the stock plunged significantly and had become a penny stock, with genuine fears of the company going into bankruptcy.

However, some keen handling of the business has brought the company and the stock back in track. However, it rallied to $35.55 a share at the start of 2019. It is again being looked upon as a major player in the chip space. However, it would be interesting to figure out whether the stock is primed for a bigger move.

Bright Road Ahead For AMD Stock?

When the rally happened earlier this year, there had been genuine hopes of a stronger rally but from the month of June up until August, the AMD stock remains range-bound. The breakout that many had hoped for has not yet come this year.

[Free Report] Which Tech Stock Could Disrupt A Multi-Billion Dollar Mega Sector?

That being said, it is important to note that the past 12 months have been a particularly tough period for the chip industry at large. The issue of oversupply had been one of the most troubling issues for the industry and that had led to the consolidation of many stocks in the industry.

stocks to watch 2019 AMD

Additionally, the lack of demand from crypto miners had also been an issue with many chip makers and it has been one of the bigger factors behind the AMD stock’s failure to breakout.

However, it needs to be pointed out that the chip market is expected to turn around and the multiples of the AMD stock make it attractive. The company is currently trading at 27.5 times its earnings for the following year and that is far cheaper valuation than its peers in the same industry as Nvidia.

Continue Reading
Click to comment

Featured

Stock Price Premarket Update – October 17, 2019

A. Lawrence

Published

on

Liberty Defense (SCAN) (LDDFF) Signs University of Wisconsin to Test HEXWAVE

MADISON, WI and VANCOUVER, Oct. 17, 2019 /PRNewswire/ – Liberty Defense Holdings Ltd. (“Liberty”) (TSXV: SCAN; FRANKFURT: LD2; OTCQB:LDDFF), a leading concealed weapons detection solutions company, is announcing that it has signed a collaboration agreement (“CoA”) with the University of Wisconsin Police Department (“UWPD”) to beta test HEXWAVE on campus.

Click For Full Press Release


Biotech Stocks To As Sector ETF’s Climb Higher

This week, both the biotech and healthcare ETF’s (IBB & XLV) took off. Even as the broader market saw sideways trading, the bullish trend persists for these two sector ETF’s. Given this, it may be time to pay close attention to a few smaller-cap names and these markets trend higher.

Read More


These Healthcare & Biotech Stocks Deserve Your Attention This Month

Stronger-than-expected third-quarter earnings from UnitedHealth Group and Johnson & Johnson helped healthcare stocks rally this week. The third-quarter results of UnitedHealth Group and Johnson & Johnson beat analysts’ expectations. With this in mind, healthcare and biotechnology stocks are in focus this month.

See For Yourself


stock price newsletter update

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Featured

Liberty Defense (SCAN) (LDDFF) Signs University of Wisconsin to Test HEXWAVE

Joe Samuel

Published

on

stock price news

MADISON, WI and VANCOUVER, Oct. 17, 2019 /PRNewswire/ – Liberty Defense Holdings Ltd. (“Liberty”) (TSXV: SCAN; FRANKFURT: LD2; OTCQB:LDDFF), a leading concealed weapons detection solutions company, is announcing that it has signed a collaboration agreement (“CoA”) with the University of Wisconsin Police Department (“UWPD”) to beta test HEXWAVE on campus.

UW-Madison is known as one of the top universities in the country, and is the oldest and largest public university in the state of Wisconsin. The UW’s academic and athletic success attracts tens of thousands to the campus each year.

HEXWAVE uses 3D radar imaging and artificial intelligence, primarily to detect and identify weapons, as well as other threats and anomalies without obstructing the movement of large groups of people. HEXWAVE enables the implementation of a layered defense strategy, which provides security teams with more time to manage threats by detecting them at the perimeter of a property.

“It is a privilege to work with the University of Wisconsin and its Police Department, such a well-established and respected education institution,” said Bill Riker, CEO of Liberty Defense. “We are looking to expand our understanding of the needs of educational environments, including open campuses. We are proud to have the opportunity to contribute and draw upon the Department’s expertise.”

Universities are a major category in the public venues market vertical, making this partnership key for Liberty’s continued development of HEXWAVE.

“The security of our campus is, of course, a top priority,” said Kristen Roman, Chief of Police at UW-Madison. “We are excited to have the opportunity to be the first campus to test this new technology. We understand how important it is for organizations to keep innovating when it comes to security and we look forward to kicking off the testing in 2020.”

This beta testing phase is a key part of HEXWAVE’s development process. Testing the system in operational and diverse facilities can help to ensure that it is aligned to market requirements. Beta testing is expected to begin later in 2019 and progress into 2020. Liberty will also beta test HEXWAVE at FC Bayern Munich’s Allianz Arena in Germany, Rogers Arena in Vancouver, British Columbia, Maryland Stadium Authority’s Camden Yards Complex, in the state of Utah, with the Virginia Division of Capitol Police, in Sleiman shopping centers, in a Hindu temple, in the Metro Toronto Convention Centre, and in Toronto Pearson International Airport.

On Behalf of Liberty Defense
Bill Riker
CEO & Director

About Liberty Defense
Liberty provides security solutions for concealed weapons detection in high volume foot traffic areas and has secured an exclusive license from Massachusetts Institute of Technology (MIT), as well as a technology transfer agreement, for patents related to active 3D radar imaging technology that are packaged into the HEXWAVE product. The system is designed to provide discrete, modular and scalable protection to provide layered, stand-off detection capability. This is intended to provide a means to proactively counter evolving urban threats. The sensors with active 3D radar imaging and Artificial Intelligence (AI)-enhanced automatic detection are designed to detect metallic and non-metallic firearms, knives, explosives and other threats. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions. Learn more: LibertyDefense .com

About the University of Wisconsin (UW)
UW is a public research university in Madison, Wisconsin. Founded when Wisconsin achieved statehood in 1848, UW is the official state university of Wisconsin, and the flagship campus of the University of Wisconsin System. It was the first public university established in Wisconsin and remains the oldest and largest public university in the state.

FORWARD-LOOKING STATEMENTS

When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of their respective officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because the parties can give no assurance that such statements will prove to be correct. The forward-looking statements and information in this press release include, amongst others, information relating to the expectation of future CoAs and validation of technology. Such statements and information reflect the current view of Liberty. There are risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.

Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading

Biotechnology

Sernova (SVA) (SEOVF) Finds C-Peptide In Phase I/II Fasting Patient

Jon Phillip

Published

on

biotechnology stocks to buy now

Mr. Dominic Gray reports

SERNOVA CONFIRMS ENDURING LEVELS OF FASTING C-PEPTIDE IN BLOODSTREAM OF FIRST PATIENT IN ITS PHASE I/II CLINICAL TRIAL FOR TYPE-1 DIABETES

Sernova Corp. (SVA) (SEOVF) has detected enduring levels of C-peptide (measured up to 30 days and continuing), a biomarker of transplanted beta cell insulin production, in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes.

The detection of fasting C-peptide in the bloodstream of our first patient, in addition to Sernova’s recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the body’s varied need for insulin production. This is an important step forward and evidence of ongoing islet engraftment within the Cell Pouch.

“Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch,” said Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago and study principal investigator. “We look forward to reporting ongoing results in additional patients as the trial progresses.”

The entry criteria of Sernova’s clinical study require patients to be C-peptide negative upon enrolment. C-peptide measured in the bloodstream is a biomarker of insulin and is widely used as a measure of insulin production by islet cells. C-peptide is typically measured following overnight fasting (fasting C-peptide) and during a glucose tolerance test (glucose-stimulated C-peptide). Together these measures provide an index of the patient’s ability to control blood glucose through their production of insulin.

With the goal of improved blood glucose control and stabilization of fluctuating blood sugar levels commonly experienced in people with type-1 diabetes, a normalizing response can also decrease the likelihood of life threatening hypoglycemic unaware events, a key efficacy measure in the Sernova trial.

Sernova’s clinical trial is continuing active recruitment and enrollment of study participants and further results will continue to be reported as the study progresses.

ABOUT SERNOVA’S CLINICAL TRAIL

Sernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in participants with diabetes and hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Importantly, patients enrolled in Sernova’s clinical trial are incapable of producing C-peptide prior to implantation of Sernova’s Cell Pouch and therapeutic cells.

Eligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regards to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients will be then further followed for one year to assess longer-term safety and efficacy.

For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details please visit www.pwitkowski.org/sernova.

ABOUT SERNOVA’S CELL POUCH

The Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. The device is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells which then release proteins and hormones as required to treat disease. The device along with therapeutic cells has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem-cell derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body.

We seek Safe Harbor.

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

© 2019 Canjex Publishing Ltd. All rights reserved. View original source: https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aSVA-2820121&symbol=SVA&region=C

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com